Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
VANCOUVER, Washington, Oct. 17, 2017 -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that management will hold an investment community conference call on Thursday, October 19, 2017, at 1:00 p.m. PT / 4:00 p.m. ET to discuss the Company’s recent meeting with the FDA and other clinical trial and regulatory developments.
Conference Call and Webcast Instructions
Interested participants and investors may access this conference call by dialing 877-407-2986 (U.S./Canada) or 201-378-4916 (international).
A live audio webcast may also be accessed via CytoDyn’s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 60 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download and install any necessary software. The webcast can also be accessed via the following link: http://cytodyn.equisolvewebcast.com/10-19-17.
A replay of the conference call will be available until December 19, 2017. To access the replay, interested parties may dial 877-660-6853 (U.S./Canada) or 201-612-7415 (international); Conference ID: 13672522.
CONTACTS:
Investors:
LHA Investor Relations
Jody Cain
Phone: 310-691-7100
E-mail: [email protected]
Media:
Joan E. Kureczka
Bioscribe, Inc.
Phone: 415-821-2413
Email: [email protected]
